Masitinib monotherapy in canine epitheliotropic lymphoma.

Item

http://www.wikidata.org/entity/Q55043104

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Masitinib monotherapy in canine epitheliotropic lymphoma.

@en

Masitinib monotherapy in canine epitheliotropic lymphoma.

@nl

type

Item

label

Masitinib monotherapy in canine epitheliotropic lymphoma.

@en

Masitinib monotherapy in canine epitheliotropic lymphoma.

@nl

prefLabel

Masitinib monotherapy in canine epitheliotropic lymphoma.

@en

Masitinib monotherapy in canine epitheliotropic lymphoma.

@nl

P1476

Masitinib monotherapy in canine epitheliotropic lymphoma.

@en

P2093

D Betz

http://www.w3.org/2001/XMLSchema#string

E Teske

http://www.w3.org/2001/XMLSchema#string

M Kessler

http://www.w3.org/2001/XMLSchema#string

M Kiupel

http://www.w3.org/2001/XMLSchema#string

N Holtermann

http://www.w3.org/2001/XMLSchema#string

P2860

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

A unique autophosphorylation site in the platelet-derived growth factor alpha receptor from a heterodimeric receptor complex

Circumventing cancer drug resistance in the era of personalized medicine.

Treatment of cutaneous T cell lymphoma: current status and future directions.

Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.

The MRP family of drug efflux pumps.

Total skin electron beam therapy as palliative treatment for cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia

P304

127-135

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/VCO.12157

http://www.w3.org/2001/XMLSchema#string

P478

14 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

Johannes Hirschberger

P577

2015-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281780940

http://www.w3.org/2001/XMLSchema#string

P698

26364581

http://www.w3.org/2001/XMLSchema#string